UqbaKhanMD

Gastrointestinal Cancer, Hematologic Oncology

Assistant Professor Weill Cornell Medicine

Overview of Dr. Khan

I am board certified oncologist and hematologist. I specialize in treating various cancers particularly gastrointestinal cancers including colon, gastric, esophageal, liver and pancreas cancer.

Office
501 6th St
Brooklyn, NY 11215
Book by Phone+1(217) 247-3054

Education & Training

New York Presbyterian HospitalFellowship, Advanced GI Oncology, 2018 - 2019
St Agnes HealthCareResidency, Internal Medicine, 2012 - 2015
Allama Iqbal Medical CollegeClass of 2008

Certifications & Licensure

NY State Medical License 2018 - 2025
MI State Medical License 2015 - 2018
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

New York Rising Stars 2020 Super Doctors, 2020
Merit Award American Society of Ccliniccal Oncology, 2018

Clinical Trials

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Start of enrollment: 2019 Jul 22
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

42 citations
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
Petros Fessas, Ahmed Kaseb, Yinghong Wang, Anwaar Saeed, David Szafron
Journal for Immunotherapy of Cancer. 2020-08-01
2 citations
Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers.
Frederic Karim, Adina Amin, Marie Liu, Nivetha Vishnuvardhan, Saif Amin
Cancers. 2023-08-14
17 citations
Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment.
Uqba Khan, Kaylee Ho, Eun Kyeong Hwang, Cristian Peña, Julianna Brouwer
American Journal of Clinical Oncology. 2021-04-06

Lectures

Phase II study of a telomerase-specific oncolytic adenovirus (OBP-301, Telomelysin) in combination with pembrolizumab in gastric and gastroesophageal junction adenocar...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Antibiotics May Blunt Cancer Immunotherapy ResponseMay 14th, 2019